LQDA VS NVO Stock Comparison

Performance

LQDA
100/100

LQDA returned 32.09% in the last 12 months. Based on SPY's performance of -13.52%, its performance is above average giving it a score of 100 of 100.

NVO
100/100

NVO returned 70.22% in the last 12 months. Based on SPY's performance of -13.73%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

LQDA
88/100

4 analysts offer 12-month price targets for LQDA. Together, they have an average target of 12, the most optimistic target put LQDA at 17 within 12-months and the most pessimistic has LQDA at 3.

NVO
50/100

1 analysts offer 12-month price targets for NVO. Together, they have an average target of 0, the most optimistic target put NVO at 0 within 12-months and the most pessimistic has NVO at 0.

Sentiment

LQDA
68/100

LQDA had a bullish sentiment score of 67.78% across Twitter and StockTwits over the last 12 months. It had an average of 2.48 posts, 3.23 comments, and 3.61 likes per day.

NVO

"Sentiment" not found for NVO

Technicals

LQDA
29/100

LQDA receives a 28 of 100 based on 14 indicators. 3 are bullish, 9 are bearish.

NVO
50/100

NVO receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

Earnings

LQDA
10/100

LQDA has missed earnings 11 times in the last 20 quarters.

NVO
46/100

NVO has missed earnings 3 times in the last 20 quarters.

Profit

LQDA
10/100

Out of the last 20 quarters, LQDA has had 0 profitable quarters and has increased their profits year over year on 0 of them.

NVO
90/100

Out of the last 20 quarters, NVO has had 20 profitable quarters and has increased their profits year over year on 15 of them.

Volatility

LQDA
48/100

LQDA has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

NVO
53/100

NVO has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Liquidia Corporation Common Stock Summary

Nasdaq / LQDA

Healthcare

Biotechnology

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Novo-Nordisk A/S Summary

New York Stock Exchange / NVO

Healthcare

Biotechnology

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Power up your portfolio